Literature DB >> 22994666

Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome.

Stephanie J Martin1, Madeleine Duvic.   

Abstract

BACKGROUND: Mycosis fungoides (MF) and the Sézary syndrome (SS) are non-Hodgkin's lymphomas that present with cutaneous lesions. Sézary syndrome is characterized by blood involvement, exfoliative eryrthroderma, lymphadenopathy, pruritus, keratoderma, and immunosuppression. This study was to estimate the prevalence of palmoplantar keratoderma and tinea pedis in Sézary syndrome and to analyze the effectiveness of anti-fungal treatment.
METHODS: We conducted a retrospective review of 1562 prospectively collected patients at the MD Anderson Cancer Center Cutaneous Lymphoma Clinic over sixteen years. All patients' palms and soles were evaluated for clinical evidence of keratoderma (hyperkeratosis) and for dermatophytosis (tinea pedis or unguum) by examining scales under 10% potassium hydroxide by light microscopy for hyphae.
RESULTS: Of 138 Sézary syndrome patients (88 men, 50 women, median age at diagnosis 64 years), 85 (61.6%) had palmoplantar keratoderma; 45 of the 85 Sézary syndrome patients (52.9%) also had coexisting tinea pedis. Only 14 (10.1%) had tinea pedis without keratoderma. Treatment for tinea pedis resulted in microscopy cure of keratoderma in 12 of 45 (26.7%) patients and clinical improvement.
CONCLUSIONS: The prevalence of palmoplantar keratoderma in Sézary syndrome is 61.6%, with co-existing tinea pedis found in 52.9%. Palmoplantar keratoderma with tinea pedis showed clinical improvement with fungicidal therapy suggesting that tinea often contributes to the pathogenesis and severity of Sézary syndrome-related keratoderma.
© 2012 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22994666     DOI: 10.1111/j.1365-4632.2011.05204.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  4 in total

1.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Lauren C Pinter-Brown; Francine M Foss; Lubomir Sokol; Jeffrey L Jorgensen; Pramoda Challagundla; Karen M Dwyer; Xiaoping Zhang; Michael R Kurman; Rocco Ballerini; Li Liu; Youn H Kim
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

2.  A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.

Authors:  Camille Luherne; Sarah Menguy; Thomas Ferte; Marie Beylot-Barry; Julien Seneschal; Brigitte Milpied; Jean-Philippe Vial; Audrey Gros; Samuel Amintas; Béatrice Vergier; Anne Pham-Ledard
Journal:  Acta Derm Venereol       Date:  2022-09-06       Impact factor: 3.875

3.  Fingerprint loss in two patients with Sézary syndrome: clinical and dermatoscopic evaluation.

Authors:  Shamir Geller; Patricia L Myskowski
Journal:  J Dtsch Dermatol Ges       Date:  2020-10-08       Impact factor: 5.584

4.  Plantar keratoderma of Sézary syndrome.

Authors:  Konstantinos C Fragkos
Journal:  Clin Case Rep       Date:  2017-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.